ResearcherLanzhou University Second HospitalNo recent work listed
Yanming Zhou
Matched on ORCID iD 0000-0002-8684-7485; OpenAlex author ID A5031497262. Sources: ClinicalTrials.gov.
Their work
- Papers
- 8 (first author 0, last author 3)
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 1
- Collaborators
- 11
2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper, 1 trial · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper
Papers 8
- Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literature. Co-author DOI 10.1007/s13304-021-01089-1↗
- Pathological complete response after neoadjuvant therapy for pancreatic ductal adenocarcinoma does not equal cure. Co-author DOI 10.1111/ans.16665↗
- Distal pancreatectomy with en bloc celiac axis resection for pancreatic cancer: a pooled analysis of 109 cases. Last author DOI 10.1007/s13304-020-00826-2↗
- Impact of tumor size on survival of patients with resected pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Co-author DOI 10.1186/s12885-018-4901-9↗
- Impact of diabetes mellitus on clinical outcomes of pancreatic cancer after surgical resection: A systematic review and meta-analysis. Last author DOI 10.1371/journal.pone.0171370↗
- Histopathologic tumor invasion of superior mesenteric vein/ portal vein is a poor prognostic indicator in patients with pancreatic ductal adenocarcinoma: resul… Last author DOI 10.18632/oncotarget.15938↗
- Second pancreatectomy for recurrent pancreatic ductal adenocarcinoma in the remnant pancreas: A pooled analysis. Co-author DOI 10.1016/j.pan.2016.09.015↗
- Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. Co-author DOI 10.1007/s00268-012-1461-z↗
Trials 1
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jun You · 2 shared papers, 2021–2022 · strength 0.45
- Paper Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systemati… DOI 10.1007/s13304-021-01089-1↗
- Paper Pathological complete response after neoadjuvant therapy for pancreatic ductal adenocarcinoma does not equal cure. DOI 10.1111/ans.16665↗
- Xiaoying Si · 3 shared papers, 2016–2018 · strength 0.27
- Paper Impact of tumor size on survival of patients with resected pancreatic ductal adenocarcinoma: a systematic review and me… DOI 10.1186/s12885-018-4901-9↗
- Paper Histopathologic tumor invasion of superior mesenteric vein/ portal vein is a poor prognostic indicator in patients with… DOI 10.18632/oncotarget.15938↗
- Paper Second pancreatectomy for recurrent pancreatic ductal adenocarcinoma in the remnant pancreas: A pooled analysis. DOI 10.1016/j.pan.2016.09.015↗
- Huaxing Wu · 1 shared paper, 2022 · strength 0.22
- Jianfa Lan · 1 shared paper, 2020 · strength 0.16
- Bin Hu · 1 shared paper, 2018 · strength 0.11
- Debang Li · 1 shared paper, 2018 · strength 0.11
- Ailin Song · 1 shared paper, 2017 · strength 0.09
- Xinghua Lv · 1 shared paper, 2017 · strength 0.09
- Yumin Li · 1 shared paper, 2016 · strength 0.08
- Donghui Xu · 1 shared paper, 2012 · strength 0.04
- Bin Li · 1 shared paper, 2012 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.